Immunity Pharma Ltd. (IPL) develops therapies for neuro-degenerative diseases with an initial focus on Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. While there is currently no cure for ALS, there is massive market potential for an ALS therapy.
IPL’s lead drug, IPL344, originates from the research laboratory of Prof. Irun Cohen at the Weizmann Institute of Science, Israel.
IPL’s drugs are peptides with biologic activity. The peptides stimulate therapeutic cell-signaling processes that are often down-regulated during neurodegenerative disease. The drugs mitigate disease progression by inducing survival-supporting processes, including reduction of inflammation and reduction of programed cell death (apoptosis).
The lead drug, IPL344, is currently entering an open-label, phase 1/2a clinical trial with ALS patients.